A multiplex, real-time TaqMan assay was designed to identify clinical isolates carrying plasmid-mediated ampC genes. The specificity and sensitivity of this assay were 100% when testing characterized AmpC/non-AmpC-producing isolates and randomly selected clinical isolates. This is a rapid assay that can be performed in a clinical microbiology laboratory.
primer/probe sequences annealed with 100% specificity to the target gene variants listed in Table 1 . TaqMan probes specific for each ampC product and ribosomal DNA were labeled 5= with 6-carboxyfluorescein (FAM) and hexachlorofluorescein (HEX) fluorescent dyes, respectively. Fluorophores attached 3= included black hole quencher-1 and Iowa black FQ, respectively. Real-time multiplex PCR was performed using the Rotor-Gene Q (Qiagen, Valencia, CA) system with fluorescence acquisition in the green channel to detect ampC amplification (FAM) and in the yellow channel to detect 16S ribosomal DNA amplification (HEX) as a control for DNA integrity.
Test or positive-control organisms were cultured as previously described (15) . Total DNA was extracted from an overnight culture using the DNeasy blood and tissue kit (Qiagen). Multiplex PCR was performed using a 50-l final reaction volume. Each PCR mixture contained a 1ϫ final concentration of QuantiTect multiplex buffer (Qiagen); 100 M primers CMY2-F1 4P1, CMY2-R1  4P1, ACT-F1 4P1, ACT-R1 4P1, DHA-F3 4P1, DHA-R3 4P1,  MOX-F1 4P1, MOX-R1 4P1, ACC-F2 4P1, ACC-R2 4P1, 16sr RNAEcKp-F1, and 16srRNAEcKp-R1; 7.5 M CMY2-Taqprobe 4P1 and FOX1-Taqprobe 4P1; 5 M ACT-Taqprobe 4P1; 1.25 M DHA3-Taqprobe 4P1; 1 M 16srRNAEcKp-probe; 0.625 M MOX-Taqprobe 4P1 and ACC2-Taqprobe 4P1 (Table 1) . Template DNA (2 l of eluate, ϳ250 ng) was added to 48 l of the master mix. The PCR conditions consisted of an initial denaturation step at 95°C for 15 min for HotStar Taq polymerase activation. Two-step cycling conditions followed and included 40 cycles of denaturation at 95°C for 1 min and primer/probe binding and primer extension at 55°C for 1 min. No template controls contained sterile nanopure water in place of template DNA.
The ability of the seven designed primer/probe combinations to anneal to target genes was tested first using a constructed panel of 6 E. coli transformants housing each plasmid-mediated ampC target and the conditions described above. Each sigmoidal curve in Fig. 1A represents amplification of one of the 6 families of plasmid-mediated ampC genes detected by fluorescence of FAM. To confirm that a specific primer pair amplified only one target of the predicted size, a confirmatory agarose gel was used to visualize the multiplex PCR products (data not shown). The internal control (55 bp) amplified in all isolates regardless of the presence of an ampC gene (Fig. 1B and D) . The specificity of the AmpC primer/probe pairs and internal control for all transformants tested was 100%. The designed primer/probe combinations for this real-time assay did not cross-hybridize with the chromosomal ampC gene in the tested E. coli transformants (1, 2, 3, 9, 15). This assay did detect primer dimer formation in the no-template controls of which fluorescence was observed at 26 to 28 cycles ( Fig. 1B  and D) . Previously characterized strains listed in Table 2 carrying plasmid-mediated ampC genes were tested and positively identified using the optimized multiplex real-time PCR assay. Five AmpCproducing Salmonella strains were also tested in this assay (data not shown). An additional panel of 109 ampC-negative but KPC (n ϭ 14)-, CTX-M (n ϭ 52)-, and TEM/SHV (n ϭ 43)-producing strains plus five ampC-negative Salmonella strains were evaluated. No FAM fluorescence was detected in the ampC-negative strains. However, the HEX-labeled probe for ribosomal gene detection was positive for PCR amplification in all the strains tested, indicating that the DNA extracted was of good quality and capable of being amplified and detected (Fig. 1B and D) . The specificity and sensitivity of this assay when evaluating the characterized nonAmpC-and AmpC-producing isolates were 100%. These data were validated using the endpoint AmpC multiplex PCR described as the gold standard for plasmid-mediated ampC detection (9, 15) . Using the endpoint assay, the AmpC-producing strains amplified the expected ampC gene, whereas the strains producing other ␤-lactamases were negative.
A total of 120 clinical isolates comprised of K. pneumoniae, Klebsiella oxytoca, and E. coli isolates were randomly collected from the clinical laboratory at Creighton University Medical Center (CUMC) and evaluated for susceptibility using disc diffusion and tested for the presence of plasmid-mediated ampC genes using this real-time assay (see Table S1 in the supplemental material). Of the 120 unknown isolates, 4% (5/120) were identified as plasmid-mediated AmpC producers. Three of five positive AmpC-producing isolates exhibited resistance to the third-generation cephalosporins but remained susceptible to cefepime. The remaining two ampC-positive isolates displayed susceptibility to the cephalosporins. A representation of a positive clinical isolate is shown in Fig. 1C . These studies were also validated using the endpoint AmpC multiplex assay to confirm the presence or absence of an ampC gene.
Currently, there is no recommendation by the CLSI for the detection of plasmid-mediated AmpC-producing strains. A recently written review by George Jacoby indicates the gold standard for detecting these types of isolates is the endpoint ampC multiplex developed by our laboratory in 2002 (9) . Data from the literature indicates a clinical responsibility to identify patients infected by organisms that produce a plasmid-mediated AmpC (13, 14) . The real-time TaqMan multiplex PCR assay described in this report provides a fast and easy-to-use tool to screen for plasmidmediated AmpC genes: a resistance mechanism that can be difficult to discern phenotypically and can result in a poor clinical outcome when undetected. 
